Department of Immunology, Complutense University and Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.
Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.
J Am Soc Nephrol. 2022 Jun;33(6):1137-1153. doi: 10.1681/ASN.2021101318. Epub 2022 May 11.
C3 glomerulopathy (C3G) is a heterogeneous group of chronic renal diseases characterized predominantly by glomerular C3 deposition and complement dysregulation. Mutations in factor H-related (FHR) proteins resulting in duplicated dimerization domains are prototypical of C3G, although the underlying pathogenic mechanism is unclear.
Using and assays, we performed extensive characterization of an FHR-1 mutant with a duplicated dimerization domain. To assess the FHR-1 mutant's association with disease susceptibility and renal prognosis, we also analyzed copy number variations and FHR-1 plasma levels in two Spanish C3G cohorts and in a control population.
Duplication of the dimerization domain conferred FHR-1 with an increased capacity to interact with C3-opsonized surfaces, which resulted in an excessive activation of the alternative pathway. This activation does not involve C3b binding competition with factor H. These findings support a scenario in which mutant FHR-1 binds to C3-activated fragments and recruits native C3 and C3b; this leads to formation of alternative pathway C3 convertases, which increases deposition of C3b molecules, overcoming FH regulation. This suggests that a balanced FHR-1/FH ratio is crucial to control complement amplification on opsonized surfaces. Consistent with this conceptual framework, we show that the genetic deficiency of FHR-1 or decreased FHR-1 in plasma confers protection against developing C3G and associates with better renal outcome.
Our findings explain how FHR-1 mutants with duplicated dimerization domains result in predisposition to C3G. They also provide a pathogenic mechanism that may be shared by other diseases, such as IgA nephropathy or age-related macular degeneration, and identify FHR-1 as a potential novel therapeutic target in C3G.
C3 肾小球病(C3G)是一组以肾小球 C3 沉积和补体失调为主要特征的异质性慢性肾脏疾病。导致重复二聚化结构域的因子 H 相关(FHR)蛋白突变是 C3G 的典型特征,尽管其潜在的发病机制尚不清楚。
我们使用 和 测定法,对具有重复二聚化结构域的 FHR-1 突变体进行了广泛的特征分析。为了评估 FHR-1 突变体与疾病易感性和肾脏预后的关联,我们还在两个西班牙 C3G 队列和对照人群中分析了 FHR-1 拷贝数变异和 FHR-1 血浆水平。
二聚化结构域的重复赋予了 FHR-1 与 C3 调理表面更强的相互作用能力,导致替代途径的过度激活。这种激活不涉及与因子 H 的 C3b 结合竞争。这些发现支持了这样一种情景,即突变 FHR-1 结合到 C3 激活的片段上,并招募天然的 C3 和 C3b;这导致替代途径 C3 转化酶的形成,增加 C3b 分子的沉积,克服 FH 的调节。这表明平衡的 FHR-1/FH 比值对于控制调理表面上的补体放大至关重要。与这一概念框架一致,我们表明 FHR-1 的遗传缺失或血浆中 FHR-1 的减少赋予了对 C3G 的保护作用,并与更好的肾脏预后相关。
我们的发现解释了具有重复二聚化结构域的 FHR-1 突变体如何导致 C3G 的易感性。它们还提供了一种可能与其他疾病(如 IgA 肾病或年龄相关性黄斑变性)共享的致病机制,并将 FHR-1 确定为 C3G 的潜在新的治疗靶点。